An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Schizophrenia

In brief

This study aims to evaluate whether PF-02545920 is safe and effective in the treatment of sub-optimally controlled symptoms of schizophrenia during a 12-week outpatient treatment period. The study will use the Positive and Negative Syndrome Scale (PANSS) to measure change in symptoms for PF-02545920 from baseline compared to placebo.

Key facts

Study ID

NCT01939548

Run by

Pfizer

People needed

240

Starts

2013-10-01

Expected to finish

2014-10-01

Last updated by the study team

2016-08-22

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Psychiatrically stable subjects with schizophrenia who have had a suboptimal response to current treatment
• Evidence of stable schizophrenia symptomatology greater than or equal to 3 months.
• Subjects must be on a stable medication treatment regimen greater than or equal to 2 months, including concomitant psychotropic medications.

You may not qualify if…

• History of seizures or of a condition with risk of seizures.
• Subjects with schizophrenia that have not responded at all to current treatment.
• Pregnant or nursing females, and females of child bearing potential.

Where it is running

• Birmingham Psychiatry Pharmaceutical Studies, Inc. — Birmingham, Alabama, United States
• Woodland International Research Group, INC — Little Rock, Arkansas, United States
• Comprehensive Clinical Development, Inc. — Cerritos, California, United States
• ProScience Research Group — Culver City, California, United States
• Synergy Clinical Research of Escondido — Escondido, California, United States
• Collaborative Neuroscience Network, Inc. — Garden Grove, California, United States
• Pacific Research Partners — Oakland, California, United States
• Excell Research, Inc. — Oceanside, California, United States
• Neuropsychiatric Research Center of Orange County — Orange, California, United States
• CiTrials — Riverside, California, United States
• CNRI-San Diego, LLC — San Diego, California, United States
• Sharp Mesa Vista Hospital — San Diego, California, United States
• Collaborative Neuroscience Network, Inc. — Torrance, California, United States
• Bliss Basement Pharmacy — Hartford, Connecticut, United States
• Institute of Living — Hartford, Connecticut, United States
• Yale University — New Haven, Connecticut, United States
• Comprehensive Clinical Development — Washington D.C., District of Columbia, United States
• Florida Clinical Research Center, LLC — Bradenton, Florida, United States
• Florida Clinical research Center, LLC — Brandenton, Florida, United States
• Innovative Clinical Research, Inc. — Lauderhill, Florida, United States
• Medical Research Group of Central Florida — Sanford, Florida, United States
• Comprehensive Clinical Development, Inc. — Atlanta, Georgia, United States
• Alexian Brothers Center for Psychiatric Research — Hoffman Estates, Illinois, United States
• Chinmay K. Patel, DO — Hoffman Estates, Illinois, United States
• Behavioral Health Care Associates — Schaumburg, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.